Abstract
BACKGROUND: The estimated treatment-placebo difference from fitted statistical models is often used to evaluate the treatment effect. In addition, we may use time saving as an alternative measure to assess the treatment benefit to patients. Two methods were developed to estimate saved time based on the placebo or treatment disease progression curve. OBJECTIVE: In this article, we are interested in comparing the performance of the traditional model and saved time measures with regards to the statistical hypothesis testing. METHODS: By mimicking data from the Phase 2 and 3 donanemab trials, we studied three different treatment disease progression trajectories. RESULTS: The traditional treatment-placebo difference model often has higher statistical power values than the saved time methods when sample size is small to medium. As sample size goes up, saved time methods have similar statistical power and they could be more powerful than the traditional model in some cases. CONCLUSIONS: Saved time methods may be considered in future Alzheimer's disease trials to improve the efficiency in drug discovery.